Recent Updates
Recently added Catalysts

BIIB111

Phase 3

Choroideremia | Small molecule | Rare Disease |Biogen Inc.|Last Updated: Jun 12, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedNO_TREATMENT_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment565

FDA Designations

No designations recorded

Clinical trial landscape

BIIB111 · 3 trials · 2 indications

Phase 3 2Phase 2 1
NCT03584165Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis PigmentosaChoroideremia
ENROLLING BY_INVITATION330 Analytics
NCT03496012Efficacy and Safety of BIIB111 for the Treatment of ChoroideremiaChoroideremia
COMPLETED169 Analytics
PHASE3ENROLLING BY_INVITATION
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
ChoroideremiaUnlock trial analytics
PHASE3COMPLETED
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
ChoroideremiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants with Adverse Events (AEs)
Up to 5 years
Ophthalmic Examination Assessment: Intraocular Pressure (IOP)
Up to 5 years
Ophthalmic Examination Assessment: Abnormal Slit Lamp Examination
Up to 5 years
Ophthalmic Examination Assessment: Lens Opacity Grading
Up to 5 years
Ophthalmic Examination Assessment: Anterior Chamber and Vitreous Inflammation
Up to 5 years
Ophthalmic Examination Assessment: Indirect Ophthalmoscopy
Up to 5 years
Percentage of Participants With a ≥15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart
Month 12

BCVA was assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If \<20 letters are read at 4 meters, testing at 1 meter should be performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of participants with a ≥15 -letter improvement from baseline in BCVA at Month 12 was reported for both eyes.

Mean Best-Corrected Visual Acuity (BCVA) as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart in Letters at Month 12
Month 12

BCVA was assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If \<20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eyes. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.

Ophthalmic Examination Assessment: Mean Intraocular Pressure (IOP) at Month 12
Month 12

IOP, the fluid pressure inside the eye was measured and reported in millimeters mercury (mmHg).

Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Slit Lamp Examination
Baseline, Month 12

Slit lamp examinations of study eyes included examination of Cornea, Conjunctiva, Iris, Lens, and Anterior Segment.

Ophthalmic Examination Assessment: Number of Participants With Clinically Significant Abnormalities in Dilated Ophthalmoscopy
Baseline, Month 12

Dilated Ophthalmoscopy examination of study eyes included examination of Vitreous, Macula, Peripheral retina, Choroid, and Optic nerve.

Ophthalmic Examination Assessment: Number of Participants With Lens Opacity Grading
Month 12

The following lens opacity grades are reported for categories 1-4: Nuclear Opalescence grade, Nuclear Color grade, Cortical Cataract grade, and Posterior Cataract grade. Opacification severity is graded on a decimal scale, scores can range from 0.1 (no opacity) to 6.9 (maximum opacity) for the Nuclear Opalescence and Nuclear Color grades; and scores can range from 0.1 (lens clear) to 5.9 (lens unclear) for the Cortical and Posterior Cataract grades. Category 1 includes values 1, 1.0 and 0.x, Category 2 includes values 2, 2.0 and 1.x, Category 3 includes values 3, 3.0 and 2.x, and Category 4 includes values 4, 4.0, 3.x and any values above 4. For each opacification type the higher grading scores indicate greater severity.

Spectral Domain Optical Coherence Tomography (SD-OCT): Foveal Subfield Thickness at Month 12
Month 12

SD-OCT was used to assess change in foveal subfield thickness. The measurements were taken after dilation of the participant's pupil.

SD-OCT: Total Macular Volume at Month 12
Month 12

SD-OCT was used to assess change in total macular volume. The measurements were taken after dilation of the participant's pupil.

SD-OCT: Central Horizontal Ellipsoid Width at Month 12
Month 12

SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil.

SD-OCT: Central Ellipsoid Area at Month 12
Month 12

SD-OCT was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil.

SD-OCT: Square Root of Central Ellipsoid Area at Month 12
Month 12

SD-OCT was used to assess change in square root of central ellipsoid area. The measurements were taken after dilation of the participant's pupil.

SD-OCT: Choroidal Thickness at Foveal Center at Month 12
Month 12

SD-OCT was used to assess change in choroidal thickness. The measurements were taken after dilation of the participant's pupil.

Fundus Autofluorescence (AF): Mean Total Area of Preserved Autofluorescence at Month 12
Month 12

Fundus AF was used to assess the total area of preserved AF. Areas of preserved AF were identified as well-demarcated regions of relative hyper autofluorescence (hyper AF) compared with the background areas of surrounding atrophy.

AF: Mean Square Root of Total Area of Preserved AF at Month 12
Month 12

Fundus AF was used to assess the square root of total area of preserved AF. Areas of preserved AF were identified as well-demarcated regions of relative hyper AF compared with the background areas of surrounding atrophy.

AF: Mean Distance From Foveal Center to Nearest Border of Preserved AF at Month 12
Month 12

Fundus AF was used to assess the distance from foveal center to nearest border of preserved AF.

Fundus Photography: Number of Participants With Retinal Pigment Epithelium (RPE) Hyperplasia as Per Severity
Month 12

Number of participants with RPE hyperplasia are reported for severity grades: mild, moderate, severe.

Fundus Photography: Number of Participants With Retinal Arteriolar Narrowing as Per Severity
Month 12

Number of participants with retinal arteriolar narrowing are reported for severity grades: mild, moderate, severe.

Fundus Photography: Number of Participants With Retinal Vessel Sheathing as Per Severity
Month 12

Number of participants with retinal vessel sheathing are reported for severity grades: mild, moderate, severe.

Fundus Photography: Number of Participants With Optic Atrophy/Pallor as Per Severity
Month 12

Number of participants with optic atrophy/pallor are reported for severity grades: mild, moderate, severe.

Fundus Photography: Number of Participants With Optic Disc Swelling as Per Severity
Month 12

Number of participants with optic disc swelling are reported for severity grades: mild, moderate, severe.

Microperimetry: Retinal Mean Sensitivity at Month 12
Month 12

Microperimetry was conducted to assess retinal mean sensitivity within the macula. Retinal mean sensitivity to light was measured in decibels in multiple spots across the central and peripheral retina (entire visual field). Higher numbers (decibels) indicate higher retinal sensitivity.

Microperimetry: Bivariate Contour Ellipse Area 63% at Month 12
Month 12

Microperimetry was conducted to assess bivariate contour ellipse area 63%.

Microperimetry: Bivariate Contour Ellipse Area 95% at Month 12
Month 12

Microperimetry was conducted to assess bivariate contour ellipse area 95%.

Microperimetry: Fixation Losses (in Percentage) at Month 12
Month 12

Microperimetry was conducted to assess fixation losses (in percentage) which samples the optic nerve blind spot for positive responses.

Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Day 0 (surgery) in period 1 up to last follow up visit in period 2 (approximately 2 years)

An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug/surgical procedure, whether or not related to the investigational product or with the surgical procedure. TEAEs are defined as AEs starting on or after the day of the first surgery.

Number of Participants With Vector Shedding Post-treatment at Month 3
Baseline, at Month 3

Tears (for both eyes- oculus dexter \[OD\] and oculus sinister \[OS\]), blood, urine and saliva samples were collected and tested using an appropriate assay for evidence of vector shedding. Participants with positive result for vector shredding post treatment are reported.

Number of Participants With Anti-drug Antibodies Post-treatment at Month 12
Month 12

Participants with antibodies to the REP-1 transgenic product are reported.

Vital Signs: Change From Baseline in Blood Pressure at Month 12
Baseline, Month 12

Change from baseline in Systolic and diastolic blood pressures (BP) (millimeters of mercury \[mmHg\]) were reported.

Vital Signs: Change From Baseline in Pulse Rate at Month 12
Baseline, Month 12

Change from baseline in pulse rate (beats per minute) were reported.

Secondary Endpoints

Change from Baseline in Best-Corrected Visual Acuity (BCVA)
Up to 5 years
Percentage of Participants with no Decrease from Baseline in BCVA or a Decrease from Baseline in BCVA of <5 ETDRS Letters in Choroideremia (CHM) Participants
Up to 5 years
Percentage of Participants with an Increase from Baseline in BCVA of ≥10 ETDRS Letters in CHM Participants
Up to 5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeOTHER

Treatment Arms

ArmTypeDescription
BIIB111EXPERIMENTALParticipants previously treated with sub-retinal injection of BIIB111 in antecedent studies 273CH301 (NCT03496012) and 273CH203 (NCT03507686) will be enrolled. Participants previously treated with this same sub-retinal injection (rAAV2-REP1) in antecedent studies 20150371 (NCT02553135), Pro00028599 (NCT02077361), THOR-TUE-01 (NCT02671539), CHM09/01 (NCT01461213) and REGEN2015 (NCT02407678) will also be invited for enrollment. This is a follow-up study, investigational product was administered in the previous study.
BIIB112EXPERIMENTALParticipants previously treated with sub-retinal injection of BIIB112 in the antecedent study 274RP101 (NCT03116113) will be enrolled. This is a follow-up study, investigational product was administered in the previous study.
UntreatedNO_INTERVENTIONUntreated participants who served as controls in the antecedent study 273CH301 (NCT03496012), investigating treatment with BIIB111, will be enrolled. This is a follow-up study, participants will not be administered study medication nor receive a sham surgery.
BIIB111 High DoseEXPERIMENTALParticipants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
BIIB111 Low DoseEXPERIMENTALParticipants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
Untreated Control GroupNO_INTERVENTIONParticipants will receive no sham surgery or study medication.

Interventions

NameTypeDescription
BIIB111GENETICAdministered as specified in the treatment arm.
BIIB112GENETICAdministered as specified in the treatment arm.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites25

Key Inclusion Criteria: CHM Participants a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM. XLRP Participants a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an ante...

Countries:United StatesBrazilCanadaDenmarkFinlandFranceGermanyNetherlandsUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about BIIB111

What is BIIB111 used for?

BIIB111 is an investigational small molecule being developed for the treatment of choroideremia, a rare inherited retinal disease that causes progressive vision loss. It is currently in Phase 3 clinical development and has not been approved by the FDA. The drug is administered as a retinal gene therapy.

Who makes BIIB111?

BIIB111 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. The drug is currently in Phase 3 clinical trials for the treatment of choroideremia, a rare genetic eye disorder.

What phase is BIIB111 in?

BIIB111 is in Phase 3 clinical development for choroideremia. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 program includes a completed efficacy and safety study and a long-term follow-up study that is currently enrolling participants by invitation.

What clinical trials is BIIB111 in?

BIIB111 has been studied in three clinical trials. A completed Phase 3 trial (NCT03496012) enrolled 169 male participants with choroideremia. A completed Phase 2 safety study (NCT03507686) enrolled 66 participants. An ongoing Phase 3 long-term follow-up study (NCT03584165) is enrolling 330 participants with choroideremia or X-linked retinitis pigmentosa.

Is BIIB111 the same as a gene therapy?

BIIB111 is a retinal gene therapy administered to treat choroideremia. It is being developed by Biogen and is currently in Phase 3 clinical trials. The drug is designed for male patients aged 18 years and older with choroideremia, a rare inherited eye disease.